Modern possibilities of drug treatment of uterine fibroids

Abstract

Uterine fibroids is one of the most common gynecological diseases. Modern drug therapy of uterine fibroids can reduce or reverse the symptoms of a tumor, in some cases, to avoid surgery.

Keywords

uterine fibroids / drug therapy

References

[1] Yoshino O, et al. Decreased pregnancy rate is linked to abnormal uterine peristalsis caused by intramural fibroids. Hum Reprod. 2010 Oct;25(10):2475-9. doi: 10.1093/humrep/deq222.

[2] Pez-Lopez FR, et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79:106-116. doi: 10.1016/j.maturitas.2014.06.002.

[3] The FIGO classification of causes of abnormal uterine bleeding: Malcolm G. Munro, Hilary O.D. Crithcley, Ian S. Fraser, for the FIGO Working Group on Menstrual Disorders. Int J Gynaecol Obstet. 2011 Apr;113(1):1-2. doi: 10.1016/j.ijgo.2011.01.001.

[4] Kroon B, et al. Australasian CREI Consensus Expert Panel on Trial evidence (ACCEPT) group. Fibroids in infertility - consensus statement from ACCEPT (Australasian CREI Consensus Expert Panelon Trial evidence). Aust N Z J Obstet Gynaecol. 2011;51:289-95. doi: 10.1111/j.1479-828X.2011.01300.x.

[5] Downes E, et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol. 2010 Sep;152(1):96-102. doi: 10.1016/j.ejogrb.2010.05.012.

[6] Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308:1589-92. doi: 10.1126/science.1112063

[7] Eder S, et al. Efficacy and safety oforal tranexamic acid in women with heavy menstrual bleeding and fibroids. Women’s Health (Lond, Engl). 2013;9:397-403. doi: 10.2217/whe.13.28.

[8] Naoulou B, Tsai MC. Efficacy of tranexamic acid in the treatment of idio-pathic and non-functional heavy menstrual bleeding: a systematic review. Acta Obstet Gynecol Scand. 2012;91:529-37. doi: 10.1111/j.1600-0412.2012.01361.x.

[9] Hoellen F, Griesinger G, Bohlmann MK. Therapeutic drugs in the treat-ment of symptomatic uterine fibroids. Expert Opin Pharmacother. 2013;14:2079-85. doi: 10.1517/14656566.2013.825607.

[10] Chiaffarino F, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol. 1999 Aug;106(8):857-60. doi: 10.1111/j.1471-0528.1999.tb08409.x.

[11] Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer. 2010 Sep 23;17(4):R263-71. doi: 10.1677/ERC-10-0076.

[12] Fauser BC, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and sterility. 2012;97:28-38. doi: 10.1016/j.fertnstert.2011.09.024.

[13] Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BW. Progestogensor progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database Syst Rev. 2013;2:CD008994.

[14] Depypere HT, et al. A 60-month non-comparative studyon bleeding profiles with the levonorgestrel intrauterine system from the latetransition period to estrogen supplemented menopause. Eur J Obstet Gynecol Reprod Biol. 2010;153:176-80. doi: 10.1016/j.ejogrb.2010.08.017.

[15] Moroni R, et al. Pharmacological treatment of uterine fibroids. Ann Med Health Sci Res. 2014 Sep;4 (Suppl 3): S185-92. doi: 10.4103/2141-9248.141955.

[16] Donnez J, et al. Ulipristal acetate versus leuprolideacetate for uterine fibroids. N Engl J Med. 2012;366:421-32. doi: 10.1056/NEJMoa1103180.

[17] Donnez J, et al. Long-term treatment of uterinefibroids with ulipristal acetate. Fertil Steril. 2014;101:1565-73. doi: 10.1016/j.fertnstert.2014.02.008.

RIGHTS & PERMISSIONS

Aganezova N.V.